Biotech Stocks on Investors' Radar -- Clovis Oncology, Dermira, Editas Medicine, and Endocyte
NEW YORK, September 15, 2017 /PRNewswire/ --
If you want a Stock Review on CLVS, DERM, EDIT, or ECYT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, September 14, 2017, US markets saw four out of nine sectors finishing the day in green and five in red. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 6,429.08, down 0.48%; the Dow Jones Industrial Average edged 0.20% higher, to finish at 22,203.48; and the S&P 500 closed at 2,495.62, down 0.11%. This Friday morning, DailyStockTracker.com looks at the performance of these four Biotechnology stocks: Clovis Oncology Inc. (NASDAQ: CLVS), Dermira Inc. (NASDAQ: DERM), Editas Medicine Inc. (NASDAQ: EDIT), and Endocyte Inc. (NASDAQ: ECYT). This morning's free research reports on the aforesaid equities can be accessed upon registration on DailyStockTracker.com at:
http://dailystocktracker.com/register/
Clovis Oncology
On Thursday, shares in Boulder, Colorado headquartered Clovis Oncology Inc. recorded a trading volume of 862,239 shares. The stock ended the session 1.06% lower at $70.03. The Company's shares have gained 17.30% over the previous three months, 140.65% in the past twelve months, and 57.65% on an YTD basis. The stock is trading above its 200-day moving average by 10.69%. Moreover, shares of Clovis Oncology, which focuses on acquiring, developing, and commercializing anti-cancer agents in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 42.83.
On August 17th, 2017, research firm Evercore ISI initiated an 'In-line' rating on the Company's stock, with a target price of $73 per share. Visit us today and download your complete report on CLVS for free at:
http://dailystocktracker.com/registration/?symbol=CLVS
Dermira
Menlo Park, California headquartered Dermira Inc.'s stock closed the day 2.71% higher at $26.53 with a total trading volume of 346,043 shares. The Company's shares have advanced 12.51% in the past month. The stock is trading above its 50-day moving average by 1.99%. Additionally, shares of Dermira, which engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the US, have an RSI of 63.26. The complimentary research report on DERM can be accessed at:
http://dailystocktracker.com/registration/?symbol=DERM
Editas Medicine
Shares in Cambridge, Massachusetts-based Editas Medicine Inc. recorded a trading volume of 813,667 shares. The stock ended yesterday's trading session 0.09% higher at $21.10. The Company's shares have advanced 35.00% over the previous three months, 40.95% in the past twelve months, and 30.01% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 14.77% and 12.64%, respectively. Furthermore, shares of Editas Medicine, which operates as a genome editing company, have an RSI of 60.93. Register for free on DailyStockTracker.com and download the research report on EDIT at:
http://dailystocktracker.com/registration/?symbol=EDIT
Endocyte
West Lafayette, Indiana headquartered Endocyte Inc.'s stock finished Thursday's session 2.14% higher at $1.43 with a total trading volume of 614,352 shares, which was above their three months average volume of 489.16 thousand shares. The Company's shares have advanced 8.33% in the last month. The stock is trading above its 50-day moving average by 2.85%. Additionally, shares of Endocyte, which develops targeted therapies for the treatment of cancer and inflammatory diseases in the US, have an RSI of 57.48. Get free access to your research report on ECYT at:
http://dailystocktracker.com/registration/?symbol=ECYT
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
